AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28847527
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid (IVAA) administered after modulated electrohyperthermia (mEHT)
Trial: 28847527
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid (IVAA) administered before modulated electrohyperthermia (mEHT)
Trial: 28847527
Drug: Solely intravenous
RxNorm normalized name: English sole
DrugBank: English sole (DB10904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solely intravenous ascorbic acid (IVAA)
Trial: 26363163
Drug: Olfactory training
RxNorm normalized name: BOS TAURUS OLFACTORY BULB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olfactory training (TR group) - twice daily exposure to 4 odours (rose, eucalyptus, lemon, clove) for approximately 12 weeks
Trial: 21176784
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg modafinil + placebo
Trial: 21176784
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg THC + placebo
Trial: 21176784
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg modafinil + 15 mg THC
Trial: 15545308
Drug: M100240 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M100240 50 mg with a high-fat meal
Trial: 15545308
Drug: M100240 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M100240 50 mg under fasted conditions
Trial: 12399343
Drug: Ongoing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ongoing intervention (active treatment with care management by practice nurses over 24 months)
Trial: 1972648
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg twice a day for 4 days)
Trial: 15561050
Drug: Closed perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed perfusion system with heparin coating and centrifugal pump
Trial: 11376665
Drug: Nitroglycerin in
RxNorm normalized name: nitroglycerin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin in the form of transdermal therapeutic system releasing 5 mg of nitroglycerin in 24 h
Trial: 9259112
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg acetylsalicylic acid (ASA) per day
Trial: 3125269
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg diflunisal 2 h preoperatively and then 500 mg twice daily for 2.5 days
Trial: 3125269
Drug: Veralgin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veralgin (1 tablet twice daily beginning 2 h prior to operation)
Trial: 27184779
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered every other day for 2 weeks)
Trial: 22851734
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (100 g/d for 3 days)
Trial: 19034538
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel (Corsodyl) applied for 30 seconds
Trial: 17687578
Drug: Interactive visuo-motor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive visuo-motor therapy system (VR-based motor neurorehabilitation)
Trial: 8044962
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg/d SC for 1 month)
Trial: 2854455
Drug: Fluconazole 50
RxNorm normalized name: fluconazole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 50 mg per day orally for 14 days
Trial: 28737409
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg immediate-release tablet of ibuprofen
Trial: 20626531
Drug: Itraconazole pulse
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole pulse regimen (200 mg b.i.d. for 1 week, off for 3 weeks)
Trial: 20626531
Drug: Continuous regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous regimen (Itraconazole 100 mg b.i.d. continuously)
Trial: 17710021
Drug: High-dose I-131
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose I-131 therapy
Trial: 11778950
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B1 (75 mg, once a day) for 1 month
Trial: 11778950
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (250 mg, twice a day) for 1 month
Trial: 9472838
Drug: Venlafaxine 150
RxNorm normalized name: venlafaxine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 150 mg/day
Trial: 9472838
Drug: Venlafaxine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 200 mg/day
Trial: 2565119
Drug: Control (Drug-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Drug-free period)
Trial: 27826345
Drug: Conventional Treatment
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Treatment
Trial: 25733201
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg per day) plus Metformin (1000 mg twice per day)
Trial: 25733201
Drug: Pioglitazone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone plus Metformin
Trial: 23392759
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg two or three times a day
Trial: 20306771
Drug: Self-reported health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported health complaints and use of medicines among females
Trial: 16904773
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation (Fentanyl and Midazolam)
Trial: 10897096
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of racemic chlorpheniramine (8 mg)
Trial: 10897096
Drug: Vietnamese-tested formulation
RxNorm normalized name: Vietnamese centipede preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vietnamese-tested formulation of racemic chlorpheniramine (8 mg)
Trial: 1813860
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g vitamin C daily
Trial: 6095659
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg at bedtime)
Trial: 21271232
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (1 µg/kg BW/h for 10 min, then 0.2-0.4 µg/kg BW/h)
Trial: 16979847
Drug: Disulfiram 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 62.5 mg/day with cocaine 0.25 mg/kg
Trial: 16979847
Drug: Disulfiram 250
RxNorm normalized name: disulfiram 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 250 mg/day with cocaine 0.25 mg/kg
Trial: 16979847
Drug: Disulfiram 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 62.5 mg/day with cocaine 0.5 mg/kg
Trial: 16979847
Drug: Disulfiram 250
RxNorm normalized name: disulfiram 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 250 mg/day with cocaine 0.5 mg/kg
Trial: 16979847
Drug: Cocaine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 0.25 mg/kg
Trial: 15482040
Drug: Manual-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual-based cognitive-behavioral treatment for anxiety
Trial: 15482040
Drug: Increased involvement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased involvement during therapy (positive involvement shifts)
Trial: 10342793
Drug: 1.25 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/day bendrofluazide
Trial: 2812168
Drug: Daily machine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily machine haemofiltration (MHF)
Trial: 1251146
Drug: Sustained-release KC1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release KC1 preparation
Trial: 1251146
Drug: Non-sustained-release KC1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-sustained-release KC1 coated tablet
Trial: 30739130
Drug: Toreforant 30
RxNorm normalized name: Toreforant
DrugBank: Toreforant (DB12522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toreforant 30 mg/day (weeks 0-52)
Trial: 30739130
Drug: Placebo (weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (weeks 0-12) followed by toreforant 30 mg/day (weeks 12-52)
Trial: 24359521
Drug: Baoji Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g
Trial: 24359521
Drug: Dummy Baoji
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy Baoji Tablets 0.9 g and Baoji Pills 3.7 g
Trial: 24359521
Drug: Dummy Baoji
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g
Trial: 16878346
Drug: Levetiracetam 1000
RxNorm normalized name: levetiracetam 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 1000 mg immediate release (IR) formulation
Trial: 10885587
Drug: Ibuprofen 7
RxNorm normalized name: hydrocodone-ibuprofen 7.5 mg-200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 7 mg/kg in suspension
Trial: 10885587
Drug: Ibuprofen 200
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 or 400mg as effervescent granules
Trial: 9058443
Drug: Inulin (30-35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (30-35 g/d) for 1 week
Trial: 28288613
Drug: Anti-gravity treadmill
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-gravity treadmill (alter G®) treatment, 20 min sessions, 2-3 times per week for 6 weeks
Trial: 18555997
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV 6/11/16/18 vaccine
Trial: 12556649
Drug: Amlodipine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (after dosage adjustment)
Trial: 12556649
Drug: Losartan/HCTZ (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan/HCTZ (after dosage adjustment)
Trial: 9305484
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral rehydration solution (20 g/L glucose, 94 mmol/L sodium, 292 mOsm/kg osmolality)
Trial: 9305484
Drug: Polymeric glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymeric glucose isotonic solution enriched with glutamine (18 g/L Glucidex 12, 14.6 g/L glutamine, 94 mmol/L sodium, 282 mOsm/kg osmolality)
Trial: 8409300
Drug: cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisapride 20 mg b.i.d.
Trial: 2866133
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg b.i.d.
Trial: 8409300
Drug: cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisapride 20 mg b.i.d. + ranitidine 150 mg b.i.d.
Trial: 3891488
Drug: Captopril long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril long-term treatment (75 or 150 mg daily)
Trial: 31069579
Drug: HIPEC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC treatment
Trial: 25182247
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg once daily, 15 mg if creatinine clearance was between 30 and 49 mL/min)
Trial: 1659437
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg twice daily) plus sumatriptan (300 mg orally)
Trial: 1659437
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus sumatriptan (300 mg orally)
Trial: 25793773
Drug: 3 day
RxNorm normalized name: Kathro 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 day regimen (2 injections of 7 mg/kg in 3 days)
Trial: 25793773
Drug: 7 day
RxNorm normalized name: ZonaCort 7 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day regimen (3 injections of 4 mg/kg per injection in 7 days)
Trial: 14671247
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (perindopril and indapamide for eligible participants)
Trial: 7679610
Drug: Bleomycin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin administered intravenously on a weekly basis
Trial: 7679610
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide therapy
Trial: 7679610
Drug: Radiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation treatment regimens (8 Gy in a single fraction and 20 Gy in ten fractions)
Trial: 3689634
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg day‐1) for 9 days
Trial: 28940192
Drug: Oral language
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral language programme (N = 103)
Trial: 26829343
Drug: Pelvic Floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic Floor Physical Therapy (PFPT) - 4 sessions
Trial: 25060372
Drug: Post-operative antibiotic
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative antibiotic duration >48 h
Trial: 19757213
Drug: Berberine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine (300 mg orally three times daily)
Trial: 10381042
Drug: MTX 15-20
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 15-20 mg/week
Trial: 6131683
Drug: Suxamethonium 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 5 min after recovery (group I)
Trial: 6131683
Drug: Suxamethonium 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 15 min after recovery (group II)
Trial: 6131683
Drug: Suxamethonium 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 30 min after recovery (group III)
Trial: 6131683
Drug: Suxamethonium 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1 mg kg‐1 followed by Org NC 45 (groups I, II, III)
Trial: 21428467
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride and IL-2 as maintenance therapy
Trial: 21428467
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride and IL-2 therapy
Trial: 16884465
Drug: Caudal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal group (1 ml.kg(‐1) 0.25% bupivacaine)
Trial: 10615738
Drug: Naltrexone only
RxNorm normalized name: Naltrexone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone only (50 mg once daily)
Trial: 10615738
Drug: Naltrexone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone with nicotine patches (50 mg once daily + 21 mg/24-hour for first 8 weeks, 14 mg/24-hour for last 4 weeks)
Trial: 10615738
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with nicotine patches
Trial: 1523998
Drug: Pirarubicin (THP)
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin (THP) instillation at a dose of 500 micrograms/ml, 3 times per week for 3 weeks
Trial: 1523998
Drug: Adriamycin (ADM)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (ADM) instillation at a dose of 500 micrograms/ml, 3 times per week for 3 weeks
Trial: 6497936
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg tamoxifen daily for 2 months
Trial: 30963353
Drug: Insulin-loaded liposomal
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-loaded liposomal chitosan gel
Trial: 27036515
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional therapy)
Trial: 18083469
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 mcg/kg IV for 10 minutes followed by 0.3 mcg/kg IV for 50 minutes)
Trial: 18083469
Drug: Propacetamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol (2 g IV for 10 minutes)
Trial: 16026220
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with adjunctive parent component
Trial: 16026220
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) without parent component
Trial: 11925385
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) treatment in patients with elevated progesterone levels
Trial: 11925385
Drug: ACTH administration
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH administration during suppression of endogenous gonadotrophin secretion
Trial: 8691565
Drug: G-CSF (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (200 micrograms/m2 iv) administration starting 24 hrs after chemotherapy (Group A)
Trial: 8691565
Drug: G-CSF (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (200 micrograms/m2 iv) administration after a febrile episode of 38 degrees C with neutropenia (Group B)
Trial: 8691565
Drug: G-CSF (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (Group A)
Trial: 420326
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment control periods
Trial: 2107608
Drug: Standard PN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PN solution
Trial: 109382
Drug: Butalamine hydrochloride
RxNorm normalized name: butalamine hydrochloride
DrugBank: Butalamine (DB13681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butalamine hydrochloride tablets (80 mg each), daily dose of 3 x 2 tablets
Trial: 109382
Drug: Butalamine hydrochloride
RxNorm normalized name: butalamine hydrochloride
DrugBank: Butalamine (DB13681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butalamine hydrochloride tablets (80 mg each), daily dose of 3 x 1 tablet
Trial: 26181221
Drug: Protocolized sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized sedation plus daily interruption
Trial: 21951313
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab injection (IVBI)
Trial: 21951313
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab injection (IVRI)
Trial: 21903553
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy without chlorhexidine
Trial: 14534519
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (2 mg estradiol valerate and 250 microg levonorgestrel)
Trial: 14534519
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (30 microg ethinyl estradiol and 150 microg desogestrel)
Trial: 14534519
Drug: Control phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control phase (150 mg bupropion without pretreatment)
Trial: 7784119
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (discontinuing antibiotic prophylaxis)
Trial: 2352049
Drug: Middle Ear
RxNorm normalized name: middle ear inflation device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle Ear Implant (MEI)
Trial: 2352049
Drug: Middle Ear
RxNorm normalized name: middle ear inflation device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle Ear Implant (MEI) and Hearing Aid (HA)
Trial: 30021451
Drug: Process incentives
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Process incentives for attending weekly Diabetes Prevention Program sessions
Trial: 30021451
Drug: Outcome incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outcome incentives for achieving weekly weight loss goals